Abstract
To the Editor: Pityriasis rubra pilaris (PRP) is a rare, inflammatory skin condition characterized by erythematous papulosquamous plaques with islands of sparing. Currently, there are no uniform guidelines for the management of PRP.1 Although studies and case series have suggested off-label biologics, there is a need for consensus on the treatment regimens and a comparison of the existing systemics is yet to be conducted.2-5 Our study aimed to characterize drug survival, a reflection of the drug performance in routine medical practice, and the treatment failures for patients with PRP treated with systemic therapies at the University of Pittsburgh Medical Center.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
